托吡酯联合薄芝糖肽治疗癫痫40例疗效观察

Observation on clinical therapeutic efficacy of 40 epilepsy children treated with topiramate combined ganoderma′s glycopeptides

目的探讨托吡酯与薄芝糖肽联合用药对癫痫患儿临床疗效、脑电图、体质量及认知功能的影响。方法将2007年12月至2009年12月该科收治的75例癫痫患儿随机分为两组：托吡酯＋薄芝糖肽联合治疗组（治疗组）与托吡酯单药对照组（对照组）。治疗6个月后将两组临床发作、脑电图指标、体质量及智力评估分值进行对照的开放性研究。结果治疗组40例患儿总有效率为87.5%,脑电图改善率为80.0%;对照组35例患儿总有效率为82.9%,脑电图改善率为71.4%,两组临床改善及脑电图指标比较,差异无统计学意义（P〉0.05）。两组盖塞尔发育量表（Gesell Developmental Scales）分值在用药6个月后较用药前均有下降,但差异无统计学意义（P〉0.05）。治疗组中2-3月龄、5-6月龄、11-12月龄患儿的体质量增长与对照组差异有统计学意义（P〈0.05）。结论 （1）托吡酯联合薄芝糖肽治疗癫痫患儿疗效肯定,但与托吡酯单药疗效比较,差异无统计学意义;（2）两药合用对小年龄组患儿的体质量增长具有积极的促进作用,可能有助于减轻托吡酯单药对患儿体质量抑制的不良影响;（3）托吡酯联用薄芝糖肽与托吡酯单药治疗6个月对癫痫患儿认知能力无明显影响。

Objective To investigate the clinical therapeutic efficacy of using topiramate combined ganoderma′s glycopeptides,and the influence to EEG、patients′ weight and cognitive competence,etc.Methods Using topiramate combined ganoderma′s glycopeptides to treat epilepsy children whose age arranged 2-25 mouths,all 40 patients were diagnosed as epilepsy（EP） by the first time.Then,to observe the change of seizure frequency,EEG,weight and mental development scale sores（Gesell）after 6 mouths.Results The total effectiveness of topiramate combined ganoderma′s glycopeptides was 87.5%.80.0%EEG was improved.The total effectiveness of topiramate was 82.9%,and 71.4% EEG was improved.And Change in all mental development scale sores（Gesell）of both 2 groups were no significant differences（P〈0.05）.Conclusion（1）Topiramate combined ganoderma′s glycopeptides is effective in treatment of EP;（2）Using ganoderma′s glycopeptides may be valuable for younger children;（3） There is no obvious influence to EP children′s cognitive competence.